imiquimod has been researched along with Adenocarcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fotiou, A; Gkegkes, ID; Iavazzo, C | 1 |
| Cho, SD; Han, JH; Kang, MJ; Kim, B; Kim, BY; Kim, DJ; Kim, JB; Park, JH; Park, SY | 1 |
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
| Donahue, RN; McLaughlin, PJ; Rogosnitzky, M; Zagon, IS | 1 |
4 other study(ies) available for imiquimod and Adenocarcinoma
| Article | Year |
|---|---|
Vulvar's Paget's disease treated with a combination of clock mapping and imiquimod.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Imiquimod; Paget Disease, Extramammary | 2023 |
TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Cytokines; Disease Models, Animal; Disease Susceptibility; Epithelial Cells; Gene Expression Regulation, Neoplastic; Guanosine; Humans; Imiquimod; Inflammation Mediators; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Prostate; Prostatic Neoplasms; Toll-Like Receptor 7; Transgenes; Tumor Stem Cell Assay | 2013 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.
Topics: Adenocarcinoma; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Head and Neck Neoplasms; Humans; Imiquimod; Immunity; Narcotic Antagonists; Pancreatic Neoplasms; Receptors, Opioid; RNA, Small Interfering; Up-Regulation | 2008 |